Search results for "LEED"

showing 10 items of 267 documents

Efficacy of TachoSil patches in controlling Dacron suture-hole bleeding after abdominal aortic aneurysm open repair

2009

Abstract Purpose The aim of this study is evaluate the efficacy of TachoSil® patches in controlling suture-hole bleeding after elective infrarenal abdominal aortic aneurysm (AAA) replacement with Dacron graft. Materials and methods Patients undergoing elective replacement of infrarenal AAA with Dacron grafts were prospectively randomized to TachoSil® patches (Group I) or standard compression with surgical swabs (Group II). We evaluated time to haemostasis, blood loss during the operation, blood loss after cross-clamp removal, duration of operation, drain volume, requirement for blood transfusion and surgeons rating of efficacy. Results Twenty patients were randomized (10 patients in each tr…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyBlood transfusionmedicine.medical_treatmentlcsh:SurgeryBlood Loss Surgicalsuture hole-bleedingSettore MED/22 - Chirurgia VascolareHemostaticslcsh:RD78.3-87.3Aortic aneurysmBlood Vessel Prosthesis Implantationabdominal aortic aneurysmmedicineHumansProspective StudiesProspective cohort studyAgedAged 80 and overSuturesbusiness.industryThrombinFibrinogenlcsh:RD1-811General MedicineTachoSilMiddle Agedmedicine.diseaseAbdominal aortic aneurysmSurgeryCardiac surgeryopen repairDrug CombinationsTreatment Outcomelcsh:AnesthesiologyCardiothoracic surgeryAnesthesiaFemaleSurgerybusinessCardiology and Cardiovascular MedicineAbdominal surgeryAortic Aneurysm AbdominalResearch Article
researchProduct

Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in stable anticoagulated patients with venous thromboembolism.

2018

VTE-BLEED predicts fatal and/or intracranial bleeding in patients with venous thromboembolism treated with long-term anticoagulants http://ow.ly/3hqg30iXK5a

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyMEDLINEHemorrhage030204 cardiovascular system & hematologySeverity of Illness Indexlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawPredictive Value of TestsRecurrenceSeverity of illnessMedicineHumansIn patientcardiovascular diseases030212 general & internal medicineAgedbusiness.industryAnticoagulantsVenous ThromboembolismBleedMiddle Agedequipment and suppliesPrognosisSurgeryPredictive value of testsDisease ProgressionFemalebusinessVenous thromboembolismIntracranial bleedingThe European respiratory journal
researchProduct

An Original Risk Score to Predict Early Major Bleeding in Acute Pulmonary Embolism

2021

Background Improved prediction of the risk of early major bleeding in pulmonary embolism (PE) is needed to optimize acute management. Research Question Does a simple scoring system predict early major bleeding in acute PE patients, identifying patients with either high or low probability of early major bleeding? Study Design and Methods From a multicenter prospective registry including 2,754 patients, we performed post hoc multivariable logistic regression analysis to build a risk score to predict early (up to hospital discharge) major bleeding events. We validated the endpoint model internally, using bootstrapping in the derivation dataset by sampling with replacement for 500 iterations. P…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyFramingham Risk ScoreAnemiabusiness.industryBleedCritical Care and Intensive Care Medicinemedicine.diseaseLogistic regressionPulmonary embolismBrier scoreInternal medicinemedicineDerivationCardiology and Cardiovascular MedicinebusinessMajor bleedingChest
researchProduct

Optimal management of hormonal contraceptives after an episode of venous thromboembolism

2019

Optimal management of hormonal contraception in patients with venous thromboembolism (VE) requires an individualized approach considering its potential benefits and complications during and after anticoagulant treatment. Potential benefits include prevention of pregnancy and mitigation of menstrual bleeding that is often worsened after start of anticoagulation therapy. Current evidence suggests that patients may opt for a continuation of (all forms of) hormonal contraception during anticoagulant treatment, provided that they are adequately informed by the treating physicians. Combined oral contraceptives should be stopped before anticoagulant therapy may he discontinued, preferably after th…

Quality of lifemedicine.medical_specialtymedia_common.quotation_subjectHormonal contraception030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineQuality of lifeHumansMedicineIntensive care medicineMenstrual cyclemedia_commonPregnancybusiness.industryMenstrual bleedingAnticoagulantsHematologymedicine.diseaseOptimal managementContraceptives Oral CombinedMenstrual bleedingHormonal contraception030220 oncology & carcinogenesisFemalebusinessVenous thromboembolismHormoneVenous thromboembolism
researchProduct

Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry

2016

Portal vein thrombosis may occur in cirrhosis; nevertheless, its prevalence, and predictors are still elusive. To investigate this issue, the Italian Society of Internal Medicine undertook the “Portal vein thrombosis Relevance On Liver cirrhosis: Italian Venous thrombotic Events Registry” (PRO-LIVER). This prospective multicenter study includes consecutive cirrhotic patients undergoing Doppler ultrasound examination of the portal area to evaluate the prevalence and incidence of portal vein thrombosis over a 2-year scheduled follow-up. Seven hundred and fifty-three (68 % men; 64 ± 12 years) patients were included in the present analysis. Fifty percent of the cases were cirrhotic outpatients.…

RegistrieLiver CirrhosisMaleCirrhosisHepatocellular carcinoma030204 cardiovascular system & hematologyGastroenterology0302 clinical medicineEsophageal varicesPrevalenceMedicineProspective StudiesRegistriesProspective cohort studyMultivariate AnalysiVenous ThrombosisPortal VeinAnticoagulants; Esophageal varices; Hepatocellular carcinoma; Liver failure; Splanchnic venous thrombosis; Emergency Medicine; Internal MedicineMiddle AgedPortal vein thrombosisVenous thrombosisSplanchnic venous thrombosis Anticoagulants Liver failure Hepatocellular carcinoma Esophageal varicesSplanchnic venous thrombosisItalyLiverEmergency MedicineFemale030211 gastroenterology & hepatologymedicine.symptomSettore SECS-S/01 - StatisticaHumanmedicine.medical_specialtyLiver CirrhosiSocio-culturaleEsophageal varicesAsymptomatic03 medical and health sciencesAnticoagulants Esophageal varices Hepatocellular carcinoma Liver failure Splanchnic venous thrombosisInternal medicineInternal MedicineHumansAgedHepatologyEsophageal varicebusiness.industryAnticoagulantLiver failureAnticoagulants; Esophageal varices; Hepatocellular carcinoma; Liver failure; Splanchnic venous thrombosis;AnticoagulantsSplanchnic venous thrombosimedicine.diseaseSurgeryProspective StudieSplanchnic venous thrombosis Anticoagulants Liver failure Hepatocellular carcinoma Esophageal varicesMultivariate AnalysisUpper gastrointestinal bleedingComplicationbusinessJournal of Hepatology
researchProduct

Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation

2013

Background Scores for cardio-embolic and bleeding risk in patients with atrial fibrillation are described in the literature. However, it is not clear how they co-classify elderly patients with multimorbidity, nor whether and how they affect the physician's decision on thromboprophylaxis. Methods Four scores for cardio-embolic and bleeding risks were retrospectively calculated for ≥ 65 year old patients with atrial fibrillation enrolled in the REPOSI registry. The co-classification of patients according to risk categories based on different score combinations was described and the relationship between risk categories tested. The association between the antithrombotic therapy received and t…

RegistrieMaleEmbolismAtrial fibrillation; Bleeding risk; Cardioembolic risk; Elderly; Prediction guides; Thromboprophylaxis; Aged; Aged; 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Female; Hemorrhage; Humans; Logistic Models; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Warfarin; Registries; Risk Assessment; Internal MedicineRetrospective Studiearitmiableeding risk scoreAtrial Fibrillation80 and overatrial fibrillationRegistriesStrokeAged 80 and overAspirineducation.field_of_studyElderly Atrial fibrillation Prediction guides Bleeding risk Cardioembolic risk ThromboprophylaxisPrediction guidesAtrial fibrillationCardiovascular diseaseStrokecardio-embolic scorePlatelet aggregation inhibitorcardio-embolic scores; bleeding risk scores; elderly; Atrial FibrillationFemaleRisk assessmentmedicine.drugHumanmedicine.medical_specialtyLogistic Modelcardio-embolic scoresPopulationHemorrhageRisk AssessmentelderlyCARDIOEMBOLIC RISKNOBLEEDING RISKInternal medicinemedicineElderly; Atrial fibrillation; Prediction guides; Bleeding risk; Cardioembolic riskbleeding risk scoresPrediction guideInternal MedicineHumanseducationThromboprophylaxisAgedRetrospective StudiesELDERLYbusiness.industryPlatelet Aggregation InhibitorSettore MED/09 - MEDICINA INTERNAWarfarinAnticoagulantAnticoagulantsRetrospective cohort studyAtrial fibrillation; Bleeding risk; Cardioembolic risk; Elderly; Prediction guides; Thromboprophylaxis; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Female; Hemorrhage; Humans; Logistic Models; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Warfarin; Registries; Risk Assessment; Internal Medicinemedicine.diseaseSurgeryLogistic ModelsThromboprophylaxiWarfarinbusinessPlatelet Aggregation Inhibitors
researchProduct

Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency.

2012

SummaryIndividuals with inherited factor VII (FVII) deficiency display bleeding phenotypes ranging from mild to severe, with 30% of patients having always been asymptomatic (non-bleeding). In 626 FVII-deficient individuals, by analysing data from the International Factor VII (IF7) Registry and the Seven Treatment Evaluation Registry (STER), we determined whether bleeding type at disease presentation and FVII coagulant activity (FVIIc) predict ensuing bleeds. At disease presentation/diagnosis, 272 (43.5%) individuals were non-bleeding, 277 (44.2%) had minor bleeds, and 77 (12.3%) had major bleeds. During a median nine-year index period (IP) observation, 87.9% of non-bleeding individuals at p…

RegistrieMalePediatricsFactor VII DeficiencyInternational CooperationAsymptomatic individual030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineRetrospective StudieAge FactorRegistriesYoung adultChildClinical Trials as TopicHematologyFactor VIIAge FactorsHematologyFactor VIIMiddle AgedPhenotypeTreatment OutcomeChild PreschoolFemalePresentation (obstetrics)medicine.symptomHumanAdultQuality ControlRiskmedicine.medical_specialtyAdolescentHemorrhageAsymptomaticMajor bleed03 medical and health sciencesYoung AdultInternal medicinemedicineHumansRetrospective StudiesModels Statisticalbusiness.industryMinor bleedInfantRetrospective cohort studychemistryDisease PresentationRelative riskbusiness030215 immunologyThrombosis and haemostasis
researchProduct

Mortality rate and risk factors for gastrointestinal bleeding in elderly patients

2019

Abstract Background Gastrointestinal bleeding (GIB) is burdened by high mortality rate that increases with aging. Elderly patients may be exposed to multiple risk factors for GIB. We aimed at defining the impact of GIB in elderly patients. Methods Since 2008, samples of elderly patients (age ≥ 65 years) with multimorbidity admitted to 101 internal medicine wards across Italy have been prospectively enrolled and followed-up (REPOSI registry). Diagnoses of GIB, length of stay (LOS), mortality rate, and possible risk factors, including drugs, index of comorbidity (Cumulative Illness Rating Scale [CIRS]), polypharmacy, and chronic diseases were assessed. Adjusted multivariate logistic regressio…

RegistrieMaleSettore MED/09 - Medicina Interna030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk Factors80 and over030212 general & internal medicineHospital MortalityProspective StudiesRegistriesProspective cohort studyMultivariate AnalysiAged 80 and overDiverticulosisMortality rateDiverticulosiGastric ulcerAnemiaAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Internal MedicineItalyPlatelet aggregation inhibitorFemaleGastrointestinal HemorrhageAntiplatelet drugHumanGastrointestinal bleedingmedicine.medical_specialtyLogistic ModelAnemiaSocio-culturaleAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity03 medical and health sciencesInternal medicineSeverity of illnessInternal MedicinemedicineHumansAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; Multimorbidity; Aged; Aged 80 and over; Female; Gastrointestinal Hemorrhage; Hospital Mortality; Humans; Italy; Length of Stay; Logistic Models; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Factors; Severity of Illness Index; MultimorbidityAgedPolypharmacybusiness.industryPlatelet Aggregation InhibitorRisk FactorAnemia; Anticoagulant; Antiplatelet drug; Diverticulosis; Gastric ulcer; MultimorbidityAnticoagulantMultimorbidityAnemia Anticoagulant Antiplatelet drug Diverticulosis Gastric ulcer Multimorbidity Aged Aged 80 and over Female Gastrointestinal Hemorrhage Hospital Mortality Humans Italy Length of Stay Logistic Models Male Multivariate Analysis Platelet Aggregation Inhibitors Prospective Studies Registries Risk Factors Severity of Illness Index MultimorbidityLength of Staymedicine.diseaseComorbidityProspective StudieLogistic ModelsMultivariate AnalysisbusinessPlatelet Aggregation Inhibitors
researchProduct

Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER)

2013

WOS: 000319897700018

RegistrieSevere bleedingAdultMalePediatricsmedicine.medical_specialtyTime FactorsTime FactorAdolescentFactor VII DeficiencyPROPHYLAXIS FACTOR VII DEFICIENCYFactor VIIachemistry.chemical_compoundPlasmaYoung AdultMedicineHumansRegistriesYoung adultFactor VII deficiencyChildFactor VIIbusiness.industryInfantHematologyRecombinant ProteinFactor VIIMiddle Agedmedicine.diseaseThrombosisRecombinant ProteinsClinical trialTreatment OutcomechemistryTreatment evaluationWeekly doseChild PreschoolFemaleOriginal Articles and Brief ReportsbusinessHuman
researchProduct

Current practice in managing patients on anticoagulants and/or antiplatelet agents around the time of gastrointestinal endoscopy -- a nation-wide sur…

2004

Anticoagulants and antiplatelet agents are widely used in the prophylaxis and management of thromboembolic and cardiovascular diseases. Gastrointestinal bleeding is a well-known complication of these agents. Modification of anticoagulant and antiplatelet therapy is often required in patients undergoing surgical procedures and specific recommendations for the perioperative period have been issued. Fewer data exist with regard to the use of these agents around the time of endoscopic procedures. A survey of the American Society for Gastrointestinal Endoscopy (ASGE), performed several years ago, showed a wide variation between endoscopists in the management of anticoagulants and antiplatelet ag…

Riskmedicine.medical_specialtyGastrointestinal bleedingmedicine.drug_classMEDLINEEndoscopy GastrointestinalGermanySurveys and QuestionnairesMedicineHumansIntensive care medicineBlood coagulation testmedicine.diagnostic_testbusiness.industryAnticoagulantGastroenterologyWarfarinAnticoagulantsPerioperativemedicine.diseaseSurgeryEndoscopyBlood Coagulation TestsGuideline AdherencebusinessComplicationGastrointestinal HemorrhagePlatelet Aggregation Inhibitorsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct